Modus Therapeutics pauses enrollment in Phase IIa sevuparin trial after serious adverse event
Modus Therapeutics voluntarily paused enrollment in Part 2 of its Phase IIa sevuparin trial for chronic kidney disease with anemia. A serious adverse event prompted the precautionary pause; a causal link to sevuparin has not been established. The pause was not regulator-imposed; no ongoing patient treatment required di